ASEPTIC:用复方磺胺甲噁唑进行初级抗生素预防以预防肝硬化患者发生自发性细菌性腹膜炎——一项干预性随机对照试验的研究方案
ASEPTIC试验是一项在英格兰、苏格兰和威尔士开展的多中心、安慰剂对照、双盲随机对照试验,计划纳入432例肝硬化腹水且无自发性细菌性腹膜炎(SBP)病史的成人患者,1:1随机接受口服复方磺胺甲噁唑960 mg或安慰剂每日一次共18个月,主要结局为总生存率,旨在评估初级抗生素预防能否改善生存。
要点
- 复方磺胺甲噁唑960 mg每日一次口服 vs 安慰剂,疗程18个月,随访最长48个月。
- 主要结局为总生存率;次要结局包括首次SBP时间、住院率、其他感染及耐药发生率等。
- 计划从至少30个中心招募432例肝硬化腹水且无当前或既往SBP发作的成人患者。
核心结论
- 该试验将评估复方磺胺甲噁唑用于肝硬化腹水患者的疗效、安全性和成本效果,以确定该策略能否改善临床结局。
- 作者认为,鉴于除肝移植外尚无改善失代偿期肝硬化生存的治疗,若试验结果为阳性,预期初级抗生素预防将被广泛采用。
研究设计与样本
- 多中心、安慰剂对照、双盲、随机对照试验,在英格兰、苏格兰和威尔士开展。
- 纳入18岁及以上、肝硬化腹水需利尿剂治疗或腹腔穿刺、且无当前或既往SBP发作的患者,计划从至少30个中心招募432例。
- 按1:1随机接受口服复方磺胺甲噁唑960 mg或相同安慰剂每日一次,共18个月,此后每6个月随访一次,最长可能随访48个月,最短18个月。
主要发现
- 主要结局为总生存率。
- 次要结局包括首次SBP发生时间、住院率、其他感染(包括艰难梭菌)发生率及抗菌药物耐药、患者健康相关生活质量、健康与社会照护资源使用、肝硬化相关失代偿事件发生率、肝移植以及治疗相关严重不良事件。
- 原文未报告试验结果数据。
关键数值与推荐
- 复方磺胺甲噁唑剂量为960 mg每日一次口服,疗程18个月。
- 计划招募432例患者,来自至少30个中心。
- 随访:治疗18个月后每6个月随访一次,最长48个月,最短18个月。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacterial infection is a major cause of mortality in patients with cirrhosis. Spontaneous bacterial peritonitis (SBP) is a serious and common infection in patients with cirrhosis and ascites. Secondary prophylactic antibiotic therapy has been shown to improve outcomes after an episode of SBP but primary prophylaxis to prevent the first episode of SBP remains contentious. The aim of this trial is to assess whether primary antibiotic prophylaxis with co-trimoxazole improves overall survival compared to placebo in adults with cirrhosis and ascites. METHODS: The ASEPTIC trial is a multicentre, placebo-controlled, double-blinded, randomised controlled trial (RCT) in England, Scotland, and Wales. Patients aged 18 years and older with cirrhosis and ascites requiring diuretic treatment or paracentesis, and no current or previous episodes of SBP, are eligible, subject to exclusion criteria. The trial aims to recruit 432 patients from at least 30 sites. Patients will be randomised in a 1:1 ratio to receive either oral co-trimoxazole 960 mg or an identical placebo once daily for 18 months, with 6 monthly follow-up visits thereafter (with a maximum possible follow-up period of 48 months, and a minimum of 18 months). The primary outcome is overall survival. Secondary outcomes include the time to the first incidence of SBP, hospital admission rates, incidence of other infections (including Clostridium difficile) and antimicrobial resistance, patients' health-related quality of life, health and social care resource use, incidence of cirrhosis-related decompensation events, liver transplantation, and treatment-related serious adverse events. DISCUSSION: This trial will investigate the efficacy, safety, and cost-effectiveness of co-trimoxazole for patients with liver cirrhosis and ascites to determine whether this strategy improves clinical outcomes. Given there are no treatments that improve survival in decompensated cirrhosis outside of liver transplant, if the trial has a positive outcome, we anticipate widespread adoption of primary antibiotic prophylaxis. TRIAL REGISTRATION: ClinicalTrials.gov NCT043955365 . Registered on 18 April 2020. Research ethical approval was granted by the Research Ethics Committee (South Central - Oxford B; REC 19/SC/0311) and the Medicines and Healthcare products Regulatory Agency (MHRA).
引用
- Crocombe D, Ahmed N, Balakrishnan I, et al. ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial. Trials. 2022. PMID: 36167573. doi:10.1186/s13063-022-06727-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。